CytoDyn Inc. (OTC: CYDY), a Vancouver, Wash., biotechnology company developing an HIV therapy, announced it has signed a manufacturing agreement with Samsung BioLogics worth $1 billion.
Samsung Biologics will manufacture CytoDyn’s drug leronlimab. The estimated revenue potential is based on $120,000 per patient per year. CytoDyn is in the process of submitting its Biologics Licensing Application to the U.S. Food and Drug Administration.
CytoDyn President and CEO Nader Pourhassan has said he expects…
